Medication Abortion Via Pharmacy Dispensing

• Status: Completed
• Trial end date: 2020-07-04
• Target enrollment: 0
• Participant gender: Female

Summary

This mixed-methods study follows a prospective cohort of patients receiving Mifeprex ® (mifepristone) for medication abortion dispensed by pharmacists after undergoing standard clinical evaluation. Women participating in this study will obtain mifepristone and misoprostol from the pharmacy instead of in the clinic. To assess feasibility, acceptability, and effectiveness of pharmacy dispensing of mifepristone, the study will survey patients, evaluate their clinical outcomes from electronic health records, and survey and interview pharmacists at study sites.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Daniel Grossman; University of California, San Francisco
• Collaborators: Kaiser Permanente; Planned Parenthood of the Great Northwest and the Hawaiian Islands; University of California, Davis; University of California, San Diego; University of Washington
• Treatments: Mifepristone

Criteria

Patient Inclusion Criteria:

• Women seeking medication abortion through 70 days gestation

• Eligible for Mifeprex® at a study clinical site

• English or Spanish speaking

• Willing and able to participate in the study, including willing to go to the study pharmacy to obtain mifepristone

Patient Exclusion Criteria:

• Not pregnant

• Not seeking medication abortion

• Under the age of 15

• Contraindications for medication abortion

• All pharmacists providing services at one of the study pharmacies during the study are eligible for the pharmacist survey and interview.